<DOC>
	<DOCNO>NCT02308527</DOCNO>
	<brief_summary>The purpose study investigate whether Bevacizumab ( anti-VEGF monoclonal antibody ) add backbone chemotherapy regimen ( Temozolomide , Irinotecan-Temozolomide Topotecan-Temozolomide ) demonstrate activity child relapse refractory neuroblastoma . Also , investigate whether addition Irinotecan Topotecan Temozolomide increase activity chemotherapy.The primary objective study best response ( Complete Response Partial Response ) trial treatment , within 18 24 week depend arm trial participant randomise . Secondary endpoint assess side effect , length time progression ( Progression Free Survival ) overall survival ( OS ) . This trial address two important question : - target blood vessel development use bevacizumab , ( monoclonal antibody Vascular Endothelial Growth Factor ( VEGF ) ) , add effect tumour use exist chemotherapy , compare effect exist chemotherapy alone ( temozolomide ) ? - addition second chemotherapy drug ( irinotecan topotecan ) increase effect tumour compare effect one alone ( temozolomide ) Patients age 1-21 year age relapse refractory high-risk neuroblastoma randomise one six treatment arm : Temozolomide ( T ) , irinotecan-temozolomide ( IT ) , bevacizumab-T ( BT ) , BIT ( bevacizumab-IT ) , temozolomide-topotecan ( TTo ) bevacizumab-temozolomide-topotecan ( BTTo ) .</brief_summary>
	<brief_title>Activity Study Bevacizumab With Temozolomide ± Irinotecan Neuroblastoma Children</brief_title>
	<detailed_description>This international open-label , randomise , multicentre phase II trial temozolomide ± irinotecan , without bevacizumab , treatment patient relapse refractory neuroblastoma . The study evaluate safety activity combination . Patients register trial randomise time one follow six arm ( approximately 30 patient per arm ) : T : Temozolomide BT : Bevacizumab + Temozolomide IT : Irinotecan + Temozolomide BIT : Bevacizumab + Irinotecan + Temozolomide TTo : Temozolomide + Topotecan BTTo : Bevacizumab + Temozolomide + Topotecan Randomisation via secure on-line computer-based system Cancer Research Clinical Trial Unit ( CRCTU ) , University Birmingham , United Kingdom ( UK ) patient allocate 1:1 ratio . Minimisation use ensure balance across arm important prognostic factor describe London et al . [ 10 ] : ) relapse , refractory disease , b ) early ( &lt; 18 month ) , late relapse ( ≥18 month ) c ) measurable versus evaluable disease ( i.e . disease evaluate accord RECIST versus disease detectable MIBG scan without bone marrow involvement detect local morphology ) Patients receive treatment 6 course , last 18 24 week depend arm trial randomise . Patients response ( CR , PR ) stable disease ( SD ) BEACON-Neuroblastoma trial receive 6 cycle trial treatment . If patient achieve satisfactory response ( i.e . CR , PR SD ) acceptable toxicity , treatment may extend beyond 6 cycle ( 12 cycle ) discussion Sponsor Chief Investigator ( CI ) .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion Criteria Histologically proven neuroblastoma per International Neuroblastoma Staging System ( INSS ) definition Relapsed : relapse progressed highrisk neuroblastoma Refractory high risk disease : Lack adequate response frontline therapy preclude patient proceed consolidation therapy Measurable disease cross sectional imaging ( RECIST ) evaluable disease Age ≥1 ≤21 year Informed consent patient , parent guardian Performance Status : Lansky ≥ 50 % , Karnofsky ≥ 50 % Eastern Cooperative Oncology Group ≤3 ( Patients unable walk paralysis , able sit upright unassisted wheelchair , consider ambulatory purpose assess performance score ) Life expectancy ≥12 week No bone marrow disease : Platelets ≥75 x 10^9/L ( unsupported 72 hour ) , absolute neutrophil count ≥0.75 x10^9/L ( Gcerebrospinal fluid support 72 hour ) , Haemoglobin ≥7.5 g/dL ( transfusion allow ) Bone marrow disease : Platelets ≥50 x10^9/L ( unsupported 72 hour ) , absolute neutrophil count ( ANC ) ≥0.5 x 10^9/L ( granulocyte colony stimulate factor ( GCSF ) 72 hour ) , Haemoglobin ≥7.5 g/dL ( transfusion allow ) Renal function ( within 72 hour eligibility assessment ) : Absence clinically significant proteinuria ( early morning urine dipstick &lt; 2+ ) . When dipstick urinalysis show proteinuria ≥2+ , protein : creatinine ( Pr/Cr ) ratio must &lt; 0.5 24 hour protein excretion must &lt; 0.5g Serum creatinine ≤ 1.5 upper limit normal age , high , calculate glomerular filtration rate ( radioisotope ) must ≥60 ml/min/1.73 m2 Liver function ( within 72 hour eligibility assessment ) : aspartate aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≤2.5 ULN Total bilirubin ≤1.5 upper limit normal ( ULN ) . In case liver metastasis , AST ALT ≤5 ULN Total bilirubin ≤2.5 ULN Cardiac function , shorten fraction ≥29 % echocardiogram Coagulation , patient anticoagulation must international normalize ratio ( INR ) ≤1.5 activate partial thromboplastin time ( APTT ) ≤1.5 ULN age . Anticoagulation permit long INR APTT within therapeutic limit ( accord medical standard institution ) patient stable dose anticoagulant least two week time study enrolment Blood pressure 95th centile age sex . Use antihypertensive medication permit Males female reproductive potential may participate unless agree use effective contraceptive method , duration study therapy 6 month last dose trial drug . A negative urine pregnancy test must obtain within 72 hour prior dose female postmenarche Previous treatment bevacizumab , temozolomide , irinotecan combination drug Known hypersensitivity : Any study drug component formulation , Chinese hamster ovary product recombinant human humanise antibody Prior severe arterial thromboembolic event ( e.g . cardiac ischemia , cerebral vascular accident , peripheral arterial thrombosis ) Any ongoing arterial thromboembolic event Patient &lt; 48 hour post bone marrow aspirate/trephine , &lt; 48 hour post central line insertion , &lt; Four week post major surgery , &lt; One week post core biopsy , &lt; Two week prior chemotherapy , &lt; Six week prior craniospinal metaiodobenzylguanidine ( MIBG ) therapy two week radiotherapy tumour bed , &lt; Eight week prior myeloablative therapy haematopoietic stem cell rescue ( autologous stem cell transplant ) , &lt; Three month prior allogeneic stem cell transplant , &lt; Two week last administration investigational medicinal product ( IMP ) IMPtrial Bleeding metastases Invasion major blood vessel Use enzyme induce anticonvulsant within 72 hour eligibility assessment History evidence inherit bleed diathesis significant coagulopathy risk bleeding ( i.e . absence therapeutic anticoagulation ) History abdominal fistula , gastrointestinal perforation , intraabdominal abscess active gastrointestinal bleeding within 6 month prior study enrolment Pregnant lactate patient Any uncontrolled medical condition pose additional risk patient Low probability treatment compliance Planned immunisation live vaccine</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Children</keyword>
	<keyword>Young adult</keyword>
</DOC>